Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses
Research and development	$ 6,043	$ 3,771	$ 16,500	$ 11,455
General and administrative	3,318	2,332	9,341	7,442
Change in fair value of contingent consideration	1,021	132	1,633	(110)
Total operating expenses	10,382	6,235	27,474	18,787
Operating loss	(10,382)	(6,235)	(27,474)	(18,787)
Other income (expense), net
Change in fair value of warrants liabilities	(653)	2	(652)	31
Interest income	174	101	434	175
Total other income (expense), net	(479)	103	(218)	206
Net loss	(10,861)	(6,132)	(27,692)	(18,581)
Other comprehensive loss
Foreign currency translation adjustment	(1)	(1)	(1)	(2)
Total comprehensive loss	$ (10,862)	$ (6,133)	$ (27,693)	$ (18,583)
Net loss per common share basic	$ (0.95)	$ (0.65)	$ (2.65)	$ (2.31)
Net loss per common share diluted	$ (0.95)	$ (0.65)	$ (2.65)	$ (2.31)
Weighted-average common shares outstanding used to calculate basic net loss per common share	11,436,748	9,417,705	10,443,186	8,045,513
Weighted-average common shares outstanding used to calculate diluted net loss per common share	11,436,748	9,417,705	10,443,186	8,045,513